Benzinga  Aug 11  Comment 
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the progress of its Phase 3...
StreetInsider.com  Jun 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catyalyst+Pharmaceutical+Partners+%28CPRX%29+Will+Join+Russell+Microcap+Index/9594614.html for the full story.
Forbes  Jun 6  Comment 
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they...
StreetInsider.com  Apr 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catyalyst+Pharma+%28CPRX%29+Initiates+Expanded+Access+Program+for+Firdapse/9402297.html for the full story.
StreetInsider.com  Apr 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catalyst+Pharma+%28CPRX%29%2C+BioMarin+%28BMRN%29+Enter+Amended+Licensing+Agreement/9391066.html for the full story.
TheStreet.com  Apr 9  Comment 
 DELAFIELD, Wis. (Stockpickr) -- I love trading the biotech sector. When this sector is in play, it offers traders the opportunity to capture some big moves over very short timeframes. >>5 Ways to Profit From a Crowded Short Trade Until you've...
newratings.com  Apr 2  Comment 
WASHINGTON (dpa-AFX) - Actavis plc (ACT) has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for about $100 million in cash. The deal catapults Actavis...
StreetInsider.com  Apr 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catalyst+Pharma+%28CPRX%29+Hits+Enrollment+Target+for+Pivotal+Firdapse+Phase+3/9336771.html for the full story.
newratings.com  Mar 26  Comment 
WASHINGTON (dpa-AFX) - The FDA has approved Actavis plc's (ACT) Metronidazole 1.3% Vaginal Gel, an antibiotic, for the treatment of bacterial vaginosis. Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals...
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catalyst+Pharma+%28CPRX%29+Reports+DMC+Recommendation+to+Continue+Firdapse+Phase+3/9312947.html for the full story.

You may also be interested in articles related to Catalyst Pharmaceutical Partners (CPRX):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki